Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | IKBKB | O14920 | 1/20 | 0.50 |
| ▸ | CHUK | O15111 | 1/20 | 0.50 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16475087 | 0.85 | KDM4E (0.57) | TP53KDM4EKMT2ANPSR1CYP1A2 | |
| SCHEMBL1810663 | 0.85 | TP53 (0.67) | TP53KDM4EKMT2ANPSR1CYP1A2 | |
| SCHEMBL9540885 | 0.84 | KDM4E (0.47) | TP53KDM4EKMT2ANPSR1CYP1A2 | |
| SCHEMBL4849865 | 0.84 | TP53 (0.60) | TP53KDM4EKMT2ANPSR1CYP1A2 | |
| SCHEMBL4851054 | 0.84 | KDM4E (0.66) | TP53KDM4EKMT2ANPSR1CYP1A2 | |
| SCHEMBL2896095 | 0.84 | IKBKB (0.68) | TP53KDM4EKMT2ANPSR1CYP1A2 | |
| SCHEMBL15931650 | 0.84 | KDM4E (0.62) | TP53KDM4EKMT2ANPSR1CYP1A2 | |
| SCHEMBL9542512 | 0.83 | IKBKB (0.54) | TP53KDM4EKMT2ANPSR1CYP1A2 | |
| SCHEMBL9539889 | 0.82 | TP53 (0.47) | TP53KDM4EKMT2ANPSR1CYP1A2 | |
| SCHEMBL9541069 | 0.81 | KDM4E (0.49) | TP53KDM4EKMT2ANPSR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048286-A1 | Inhibitors of Protein Tyrosine Phosphatase 1B | WYETH (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048286-A1 | Inhibitors of Protein Tyrosine Phosphatase 1B | WYETH (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048286-A1 | Inhibitors of Protein Tyrosine Phosphatase 1B | WYETH (US) | 2009-02-19 | — | — | US | disclosed |
| US-7456192-B2 | 3β-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof | PIERRE FABRE MEDICAMENT (FR) | 2008-11-25 | — | — | US | disclosed |
| US-20050203081-A1 | Inhibitors of protein tyrosine phosphatase 1B | WYETH | 2005-09-15 | — | — | US | disclosed |
| WO-2005081960-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B | WYETH (US) | 2005-09-09 | — | — | WO | disclosed |
| EP-1440075-B1 | NOVEL 3BETA-AMINO AZABICYCLOOCTANE HETEROAROMATIC AMIDE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USES THEREOF | PF MEDICAMENT (FR) | 2005-06-08 | — | — | EP | disclosed |
| US-20050080085-A1 | Novel 3beta-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof | PIERRE FABRE MEDICAMENT (FR) | 2005-04-14 | — | — | US | disclosed |
| EP-1440075-A1 | NOVEL 3BETA-AMINO AZABICYCLOOCTANE HETEROAROMATIC AMIDE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USES THEREOF | PIERRE FABRE MEDICAMENT (FR) | 2004-07-28 | — | — | EP | disclosed |
| WO-2003037904-A1 | NOVEL 3BETA-AMINO AZABICYCLOOCTANE HETEROAROMATIC AMIDE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USES THEREOF | PIERRE FABRE MEDICAMENT (FR) | 2003-05-08 | — | — | WO | disclosed |
| WO-1993013664-A2 | BIHETEROCYCLIC FUNGICIDAL COMPOUNDS | SCHERING AGROCHEMICALS LIMITED (GB) | 1993-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080085-A1 | Novel 3beta-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof | AOC3, MAOB, AOC1 | TP53 3133/4885KDM4E 2970/4885KMT2A 2929/4885 |
| US-20050203081-A1 | Inhibitors of protein tyrosine phosphatase 1B | PTPRS, PTPRO, PTPRM | TP53 1154/4885KDM4E 899/4885KMT2A 2936/4885 |
| US-20090048286-A1 | Inhibitors of Protein Tyrosine Phosphatase 1B | PTPRS, PTPRO, PTPRM | TP53 1154/4885KDM4E 899/4885KMT2A 2936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.